Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,514
  • Shares Outstanding, K 74,688
  • Annual Sales, $ 0 K
  • Annual Income, $ -53,340 K
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.50
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.73
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/14/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.15
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +47.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.22 +64.52%
on 11/21/19
0.55 -35.51%
on 12/09/19
+0.10 (+41.94%)
since 11/13/19
3-Month
0.22 +64.52%
on 11/21/19
0.55 -35.51%
on 12/09/19
-0.10 (-22.50%)
since 09/13/19
52-Week
0.22 +64.52%
on 11/21/19
2.01 -82.35%
on 03/05/19
-1.11 (-75.71%)
since 12/13/18

Most Recent Stories

More News
Sierra Oncology Reports Decreased Transfusion Requirements for Patients Treated with Momelotinib Directly Compared to Ruxolitinib at ASH Annual Meeting

New analyses of Phase 3 data highlighting momelotinib's meaningful anemia benefits in myelofibrosis presented in a poster at the 61st American Society of Hematology Annual Meeting -

SRRA : 0.35 (unch)
Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 7:00 am ET on December 8th -

SRRA : 0.35 (unch)
Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated...

SRRA : 0.35 (unch)
Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

MOMENTUM trial designed to confirm the unique benefits of momelotinib on all three hallmarks of myelofibrosis: symptoms, anemia and enlarged spleen -- Targeting enrollment of 180 symptomatic and anemic...

SRRA : 0.35 (unch)
Sierra Oncology to Present at the Jefferies 2019 London Healthcare Conference

"Building Momentum for Patients with Myelofibrosis" scheduled for 6:00 p.m. GMT on November 20, 2019 -

SRRA : 0.35 (unch)
Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib

Gilead to reduce momelotinib commercial royalty rates in exchange for equity in Sierra -- Amendments become effective upon Sierra Oncology closing a qualified financing -

SRRA : 0.35 (unch)
Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated...

SRRA : 0.35 (unch)
Sierra Oncology Announces Proposed Public Offering of Convertible Preferred Stock and Warrants

Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated...

SRRA : 0.35 (unch)
Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients -

SRRA : 0.35 (unch)
Sierra Oncology Reports Third Quarter 2019 Results

MOMENTUM Phase 3 myelofibrosis clinical trial anticipated to launch in Q4 2019 -

SRRA : 0.35 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade SRRA with:

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 0.45
1st Resistance Point 0.40
Last Price 0.35
1st Support Level 0.32
2nd Support Level 0.29

See More

52-Week High 2.01
Fibonacci 61.8% 1.32
Fibonacci 50% 1.11
Fibonacci 38.2% 0.90
Last Price 0.35
52-Week Low 0.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar